Oncology

Study: Gender, Internet Habits Influence Biosimilar Acceptance

February 15th 2021

By Tony Hagen

Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.

Roche's 2020 Losses to Biosimilars Were "Worst It Can Get"

February 9th 2021

Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.

Study: Biosimilar Use Varies by Type of Institution and Physician Characteristics

February 8th 2021

By Tony Hagen

Physician specialty and practice setting each play a significant role in whether biosimilars are administered vs originators, according to a large, cross-sectional study.

Amgen Profits Get a Ride on Biosimilar Growth

February 4th 2021

By Tony Hagen

Amgen described how a double-edged biosimilars sword has worked for and against the company's profit margin.

Pfizer Biosimilar Revenues Top $525 Million in Fourth Quarter 2020

February 3rd 2021

By Tony Hagen

Pfizer's investment in biosimilars is starting to pay off, as it now ranks these agents among its top revenue drivers.

Oncology Biosimilar Roundup for January 2021

February 2nd 2021

By Skylar Jeremias

Findings from biosimilar studies of Kanjinti (trastuzumab) and Mvasi and Zirabev (bevacizumab) rounded out our oncology biosimilar coverage in January.

Magellan Rx Reports Step Therapy Is Workhorse in Biosimilar Utilization

February 1st 2021

By Tony Hagen

The pharmacy benefit manager reported 90% biosimilar uptake among its health plans that adopted clinical management policies that included step therapy or parity usage.

Study: Bevacizumab Biosimilar Finds Acceptance in First-Line Treatment of mCRC

January 30th 2021

By Deana Ferreri, PhD

Investigators noted comparable use of bevacizumab biosimilar and reference products among patients treated for metastatic colorectal cancer (mCRC).

FDA Accepts Bio-Thera's BLA for Bevacizumab Biosimilar

January 29th 2021

By Tony Hagen

Guangzhou, China-based Bio-Thera has filed a biologics license application (BLA) with the FDA for the approval of bevacizumab biosimilar candidate BAT1706.

Vizient Predicts 7.5% Humira Price Increase Before Biosimilars Arrive

January 28th 2021

By Tony Hagen

In its annual drug price guide, Vizient predicts that US annual adalimumab (Humira) revenues could reach $24 billion before biosimilars enter the marketplace.